Bristol-Myers Squibb vs Sanofi
Bristol-Myers Squibb (BMY), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bristol-Myers Squibb is worth $124.7B on the stock market and Sanofi $115.1B: Bristol-Myers Squibb is valued at 8% more. Bristol-Myers Squibb trades at 13.5 times earnings and Sanofi at 23.9. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Sanofi's -4.48%.
Key facts
- Bristol-Myers Squibb market value
- $124.7B
- Sanofi market value
- $115.1B
- Bristol-Myers Squibb P/E
- 13.5
- Sanofi P/E
- 23.9
- Bristol-Myers Squibb revenue
- $48.2BFY to 2025-12-31
- Sanofi revenue
- $48.4BFY to 2025-12-31
- Superinvestors holding both
- 2
Market values as of .
| Measure | Bristol-Myers Squibb | Sanofi |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $124.7Bhigher | $115.1Blower |
| Revenue | $48.2Blower | $48.4Bhigher |
| Earnings | $7.1Blower | $8.7Bhigher |
| Employees | 32,500lower | 74,846higher |
| Total assets | $90Blower | $140.7Bhigher |
| Valuation | ||
| P/E | 13.5lower | 23.9higher |
| P/S | 2.6higher | 2.4lower |
| P/B | 5.3 | — |
| Dividend yield | 4.00% | — |
| Profitability | ||
| Operating margin | — | 14.5% |
| Balance sheet | ||
| Net assets | $18.5Blower | $79.2Bhigher |
| Total liabilities | $71.5Bhigher | $61.1Blower |
| Total debt | $45.1Bhigher | $20.8Blower |
| Cash on hand | $10.2Bhigher | $8.5Blower |
| Price change | ||
| Today | -3.07%lower | -0.92%higher |
| 1 year | +33.7%higher | -4.48%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Richard Pzena2.6% / <0.1%
- Sarah Ketterer<0.1% / 0.4%
Bristol-Myers Squibb only (13)
Sanofi only (5)
- Charles Brandes (founder)1.2%
- Louis Bacon0.5%
- Dodge & Cox team0.3%
- Ken Fisher0.1%
- Lee Ainslie<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Sanofi). Who owns BMY · Who owns SNY
More on Bristol-Myers Squibb
Further comparisons
Bristol-Myers Squibb against its closest peers
Sanofi against its closest peers
Learn
Questions and answers
Which is bigger, Bristol-Myers Squibb or Sanofi?
By market value, Bristol-Myers Squibb is the larger: $124.7B against $115.1B for Sanofi. By revenue in its latest fiscal year, Sanofi is the larger: $48.4B against $48.2B for Bristol-Myers Squibb.
Which has the higher P/E ratio?
Sanofi: 23.9, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Bristol-Myers Squibb: $45.1B, against $20.8B for Sanofi. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Bristol-Myers Squibb and Sanofi?
In their latest 13F filings, Richard Pzena and Sarah Ketterer hold both.
Cite this page
Funkfolio, “Bristol-Myers Squibb vs Sanofi”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-sny
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.